4.12 0.00 (0.00%)
After hours: 4:44PM EDT
|Bid||3.95 x 1400|
|Ask||4.30 x 800|
|Day's Range||4.01 - 4.13|
|52 Week Range||3.95 - 11.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 9, 2017 - Jun 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
NEW YORK, Aug. 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sandy ...
Enzo Biochem Inc. (ENZ) today announced the validation of three clinically relevant, cost-efficient biomarker detection tests for charting the progression of various cancers, especially in the field of women’s health. The validated tests complement Enzo’s POLYVIEW® immunohistochemistry (“IHC”) and in situ hybridization (“ISH”) detection platform, an enhanced diagnostic detection system used by pathologists in reading tissue biopsies and favorably cited by a leading peer review publication for showing no false positives.
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want access to our free research report on Bruker Corp. (NASDAQ: BRKR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BRKR as the Company's latest news hit the wire. On July 03, 2018, the Company announced that it has signed an agreement to acquire the entire business of Drachten, The Netherlands-based Lactotronic B.V. Lactotronic specializes in developing, manufacturing, and distributing milk analyzing equipment and instruments for the dairy industry. Active-Investors.com is currently working on the research report for Enzo Biochem, Inc. (NYSE: ENZ), which also belongs to the Healthcare sector as the Company Bruker.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 11) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
The New York-based company said it had a loss of 6 cents per share. The life sciences and biotechnology company posted revenue of $25.6 million in the period. Enzo Biochem shares have decreased 18 percent ...
Enzo Biochem Inc. , an integrated diagnostic company, today reported results for the third fiscal quarter and nine months ended April 30, 2018, in addition to noting significant progression of its strategic plan aimed at providing cost-effective, high performing and easily adaptable products and services to hospital and independent laboratories.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday June 26, 2018.
Enzo Biochem, Inc. and its subsidiary Enzo Life Sciences, Inc. today announced that the Patent Trial and Appeal Board has denied a petition filed by Hologic, Inc. for inter partes review, a procedure for challenging the validity of patent claims, against U.S.
Enzo Biochem (NYSE: ENZ ) unveils its next round of earnings Tuesday. Get prepared with Benzinga's ultimate preview for Enzo Biochem's Q2 earnings. Earnings and Revenue Enzo Biochem EPS is expected to ...
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their Q2 Earnings Call to be held on March 13, 2018, at 8:30 AM Eastern Time. To ...
On a per-share basis, the New York-based company said it had a loss of 2 cents. Losses, adjusted for pretax gains, were 4 cents per share. The life sciences and biotechnology company posted revenue of ...
Enzo Biochem, Inc. will hold a conference call to discuss fiscal 2018 second quarter results Tuesday, March 13, 2018, at 8:30 AM E.T.
Enzo Biochem, Inc. , an integrated diagnostics company, announced today validation of a cervical cancer biomarker detection test that provides a highly robust and cost-efficient solution for anatomical pathology.
LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free earnings report on Enzo Biochem, Inc. (NYSE: ENZ ). If you want access to this report all you need to do is sign ...
Stock Monitor: Enzo Biochem Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on Cancer Genetics, Inc. (NASDAQ: CGIX ), which is readily accessible ...